$1.76
+0.07 (+4.14%)
Open$1.71
Previous Close$1.69
Day High$1.77
Day Low$1.70
52W High$44.36
52W Low$19.01
Volume—
Avg Volume303.4K
Market Cap258.66M
P/E Ratio54.75
EPS$0.60
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+1,956.8% upside
Current
$1.76
$1.76
Target
$36.20
$36.20
$24.75
$36.20 avg
$54.95
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 50.41M | 45.49M | 44.34M |
| Net Income | -12,744,166 | -11,017,037 | -10,122,519 |
| Profit Margin | -25.3% | -24.2% | -22.8% |
| EBITDA | -16,231,640 | -13,211,435 | -14,610,213 |
| Free Cash Flow | -10,845,649 | -11,236,120 | -8,740,023 |
| Rev Growth | -0.9% | +9.2% | +11.8% |
| Debt/Equity | 0.67 | 0.72 | 0.74 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.87 | -1.20% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $354.05 | +0.63% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.73 | +0.98% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $449.71 | +0.71% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $776.21 | +0.46% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.03 | -0.25% | 139.7 | 43.84B |